Table 1.
Patient and treatment characteristics (n)
| Sex | Grading | ||
| Female | 19 (28.4%) | 1 | 1 |
| Male | 48 (71.6%) | 2 | 33 |
| Age | 3 | 25 | |
| Median | 71 y | Unknown | 8 |
| Mean | 71.6 y | T-stage | |
| Range | 65–82 y | 1 | 1 |
| ECOG | 2 | 10 | |
| 0 | 38 | 3 | 51 |
| 1 | 18 | 4 | 2 |
| 2 | 6 | Tx/Unknown | 3 |
| 3 | 4 | N-stage | |
| Unknown | 1 | 0 | 3 |
| Tumor site | 1 | 54 | |
| Cervical | 4 | 2 | 3 |
| Upper thoracic | 11 | 3 | 1 |
| Middle thoracic | 19 | Nx/Unknown | 6 |
| Lower thoracic | 33 | M-stage | |
| Histology | 0 | 63 | |
| Adeno | 33 | 1 | 3 |
| SCC | 34 | Mx/Unknown | 1 |
| AJCC/UICC stageI | SCC | Adeno | |
| II | 4 | 0 | |
| III | 23 | 25 | |
| IVA | 2 | 2 | |
| IVB | 1 | 2 | |
| Unknown | 4 | 4 | |
| Chemotherapy | RT technique | ||
| Neoadjuvant | 44 | APPA (two-field) | 11 |
| Definite | 23 | 3D-CRT (multi-field) | 34 |
| Agents | IMRT | 19 | |
| Platinum-taxane-based | 58 | Unknown | 3 |
| Others | 9 | ||
| Charlson scoreII | SCC | Adeno | |
| ≤ 1 | 27 | 25 | |
| > 1 | 7 | 8 | |
Adeno adenocarcinoma, IMRT intensity modulated radiation therapy, RT radiation therapy, SCC squamous cell carcinoma, 3D-CRT three-dimensional conformal radiation therapy, Unknown Due to the retrospective character of the study, y years
I8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction, IIThe final score was calculated for each patient by considering all comorbid conditions present with the exclusion of EC